MedTrace Logo

CYP2D6 Genotype on the Clinical Effect of Tamoxifen

NCT00973037 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 922

Last updated 2009-09-09

No results posted yet for this study

Summary

The purpose of this study is to investigate the impact of CYP2D6 Genotype on the clinical effects of tamoxifen using with samples from prospective randomized multicenter study(ASTRRA).

Conditions

  • Breast Neoplasms
  • Tamoxifen
  • Genotype
  • CYP2D6

Interventions

DRUG

Tamoxifen

Tamoxifen 20mg qd

Sponsors & Collaborators

  • National Cancer Center, Korea

    collaborator OTHER_GOV

  • Korean Breast Cancer Study Group

    collaborator OTHER

  • Korea University Anam Hospital

    lead OTHER

Principal Investigators

  • Eun Sook Lee, MD, PhD · Korea University Anam Hospital

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00973037 on ClinicalTrials.gov